Embedded Files
CellenVax has developed an engineering technology known as Viral Surface Engineering (VSE) through years of research, which enhances immune efficiency by attaching immune-enhancing molecules to the virus surface compared to conventional vaccines. The novel vaccine platform, VSE, possesses a high degree of versatility for the development of various virus vaccines, eliminates the need for additional processes in existing vaccine platforms, and offers a distinct advantage of not requiring separate adjuvants.
Our company is currently validating the superiority of our technology through evaluations of diverse human and animal-origin virus diseases utilizing this vaccine platform. Furthermore, the immune responses elicited by the developed vaccines undergo comprehensive clinical analyses targeting various species and organs to assess their safety.
Not a Vaccine, Novel Cell lines
Not a Vaccine, Novel Cell lines
Developed New Technology for MOA (Viral Surface Engineering)
Developed New Technology for MOA (Viral Surface Engineering)
Need of Adjuvants
Need of Adjuvants
Cell line developing platform for viral vaccines
Cell line developing platform for viral vaccines
Manufacturing process of inactivated vaccines
Manufacturing process of inactivated vaccines
Production (Technology Transfer)
Production (Technology Transfer)
Development of Porcine Epidemic Diarrhea Vaccine
Successfully applied VSEtechnology on the surface of PEDV
Fast response to mutants with same cellline system
Established scaleup process
광견병 백신 개발
핵심요소 : 광견병 바이러스 (RV) 표면에 Fc 단백질을 부착하는 데 성공
Fast response to mutants with same cellline system
Established scaleup process
닭호흡기 뉴모바이러스(aMPV) 백신 개발
핵심요소 : 닭호흡기 뉴모바이러스 (aMPV) 표면에 Fc 단백질을 부착하는 데 성공
Fast response to mutants with same cellline system
Established scaleup process
Patents
Patents
Overseas patents application
Page updated
Google Sites
Report abuse